September 20, 2024 11:17 AM EDT

FDA approves Zevra’s rare disease drug after resubmission

Lei Lei Wu

News Reporter

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare genetic disease caused by the accumulation of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves Zevra’s rare disease drug after resubmission

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

FDA ap­proves Zevra’s rare dis­ease drug af­ter re­sub­mis­sion

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA approves Zevra’s rare disease drug after resubmission